ELANVeterinary medicines
Elanco Animal Health
- Price
- $25.77
- Discount category
- Close to intrinsic value
- Analysts
- Bullish
- Next earnings
- Feb 23 · · estimated
- Pick status
- Research only
In short
- Thesis
- The market weighs the new pet products of Elanco against its debt and strong competitors, and steady share gains with lower debt through 2027 can lift its value.
- Gap
- Can close. The Q4 2026 report and 2027 guidance, expected in late February 2027, and the EU launch of Credelio Quattro in Q1 2027 show whether new products keep growth and margins up.
Company guidance: 2026 revenue $5.155 to $5.18 billion; adjusted EBITDA $1.05 to $1.065 billion; adjusted EPS $1.17 to $1.20 (, Q3 2026 results release (8-K))
Price history
About
Elanco Animal Health Incorporated (Elanco) is based in Indianapolis, Indiana. It develops, makes and sells medicines, vaccines and other products for pets and farm animals. Its Pet Health brands include Zenrelia, Credelio Quattro, Advantage and Seresto.
Its Farm Animal products serve cattle, poultry and swine. Revenue was $1,265 million in Q3 2026: Pet Health $608 million, Farm Animal $631 million and contract manufacturing and other $26 million. In April 2026 it bought AHV International, a Dutch farm animal health company.
Elanco pays no dividend. The common stock trades on the NYSE in US dollars. Elanco files 10-K and 10-Q reports.
Thesis
The price of Elanco depends on whether its new pet products keep growth and margins up while the company pays down the debt from earlier purchases. Revenue grew 9% in Q3 2026 on an organic constant currency basis, with price up 4%, and the adjusted gross margin rose 300 basis points to 56.1%. Zenrelia and Credelio Quattro gained share in the US, and Credelio Quattro became its largest US Pet Health brand.
The net leverage ratio fell to 2.9 times adjusted EBITDA at September 30, 2026, from 3.6 times at the end of 2025. For the price to hold or rise, three things must be true. Zenrelia, Credelio Quattro and the new product Befrena must keep gaining share against strong competitors.
Elanco must reach its 2026 guidance of adjusted EBITDA of $1,050 million to $1,065 million and then its 2027 outlook of high-single-digit adjusted EBITDA growth and low-double-digit adjusted EPS growth. Free cash flow must keep reducing the debt, so that interest costs fall. The Q4 2026 report, expected in late February 2027, with 2027 guidance, and the EU launch of Credelio Quattro in Q1 2027 are the next tests.
Checkpoints
- Feb 23, 2027 · est.PendingQ4 2026 results and 2027 guidance2026 adjusted EBITDA is in the guided range of $1,050 million to $1,065 million and 2027 guidance keeps high-single-digit adjusted EBITDA growth, and this passes; a result below the range or lower 2027 growth fails.
- Q1 2027 · est.PendingEU launch of Credelio QuattroElanco launches Credelio Quattro in the EU in Q1 2027, as it expects, and this passes; a delay past Q2 2027 fails.
Recent events
- November 6, 2026Elanco reported Q3 2026 results. Revenue rose 11% to $1,265 million, or 9% on an organic constant currency basis, adjusted EBITDA rose 23% to $243 million and adjusted EPS was $0.27. It raised 2026 guidance to revenue of $5,155 million to $5,180 million, adjusted EBITDA of $1,050 million to $1,065 million and adjusted EPS of $1.17 to $1.20.
- November 6, 2026Elanco said that Credelio Quattro received a positive opinion from the European Medicines Agency, and it expects to launch the product in the EU in Q1 2027. It also said that Befrena moves into full launch in Q1 2027.
- November 3, 2026Jamie Preston became Executive Vice President and Chief People Officer. Dave Kinard, who held the role, plans to retire at the end of 2026.
Show 2 older eventsHide older events
- April 30, 2026Elanco completed the purchase of AHV International, a Dutch farm animal health company that works to reduce the need for antibiotics, for an estimated total price of $241 million.
- December 5, 2025The board approved a restructuring plan that cuts about 300 jobs and moves about 300 more to growth areas or lower-cost places, with pretax charges of about $175 million.
Latest news and filings
- Last earnings
- November 6, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 23, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed elan-20260930
- 8-KEarnings releaseFiled Press release and exhibits
- 10-QQuarterly report for the period ended Jun 30, 2026Filed elan-20260630
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KShareholder vote resultsFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Mar 31, 2026Filed elan-20260331
- 8-KEarnings releaseFiled Press release and exhibits
- 10-KAnnual report for the period ended Dec 31, 2025Filed elan-20251231
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KInvestor disclosureFiled Read it on sec.gov
Risks
- Debt is high. Debt principal was $3,470 million at September 30, 2026, and net interest expense was $59 million in Q3 2026. Lower earnings would slow the payback of debt.
- Pet Health products face strong competitors, also in the markets of Zenrelia and Credelio Quattro, and from generic products. Lost share would slow growth.
- Elanco faces lawsuits. A securities class action says that Elanco made false or misleading statements about the safety and label of Zenrelia, and other lawsuits allege unlawful sales practices for flea and tick products.
- Farm animal sales depend on disease and farm economics. Poultry revenue fell 7% in Q3 2026, and an outbreak of disease could cut demand.
- Changes in tariffs, trade rules and exchange rates can change costs and reported revenue.
Key statistics
- Market cap
- $13B
- Shares of Nov 4, 2026
- EPS (trailing)
- -$0.30
- 12 months to Sep 30, 2026
- 52-week range
- $19.40 – $27.98
- To Nov 12, 2026
- Beta
- 1.73
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 5.3M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $465M
- Debt
- $3.5B
- Net debt
- $3.0B
- Net debt / EBITDA
- 2.9×
- EBITDA $1.1B, last 12 months
- Credit line
- $750M
- undrawn, to July 2029
Cash against debt
debt covered by cashnet debt $3.0B
Leverage: net debt / EBITDA
low, under 2×medium, 2× to 4×high, over 4×
When the debt is due
The last debt is due in 2032.
At September 30, 2026, Elanco had debt principal of $3,470 million: term loans of $2,620 million, Senior Notes due 2028 of $750 million at 6.40% and $100 million under its securitization facility. Finance lease liabilities were $258 million. Cash and cash equivalents were $465 million. Elanco gives net debt of $3,005 million and a net leverage ratio of 2.9 times trailing adjusted EBITDA of $1,053 million. The $750 million revolving credit facility, which matures in July 2029, had no borrowings. With interest rate swaps, the weighted average interest rate was 5.26%. Operating cash flow was $506 million for nine months. The balance sheet also has a liability for sale of future revenue of $309 million, for royalties that Elanco sold to Blackstone in May 2025.
Dividends
Elanco Animal Health does not pay a dividend.
Source: company filings and market data, read on November 12, 2026.
Questions about Elanco Animal Health
What does Elanco Animal Health do?
Elanco Animal Health Incorporated (Elanco) is based in Indianapolis, Indiana. It develops, makes and sells medicines, vaccines and other products for pets and farm animals. Its market cap is $13B at the current price of $25.77.
When does Elanco Animal Health report earnings next?
This is an estimate: Elanco Animal Health may report on February 23, 2027. It last reported results on November 6, 2026.
Is Elanco Animal Health stock below its intrinsic value?
Elanco Animal Health stock is close to intrinsic value. This is general information, not advice.
What changed recently at Elanco Animal Health?
The latest update is from November 6, 2026. Elanco reported Q3 2026 results.
What are the main risks for Elanco Animal Health?
Debt is high. Pet Health products face strong competitors, also in the markets of Zenrelia and Credelio Quattro, and from generic products. Elanco faces lawsuits.
How much debt and cash does Elanco Animal Health have?
At September 30, 2026, Elanco Animal Health had $3.5B of debt and $465M of cash.
Does Elanco Animal Health pay a dividend?
No. Elanco Animal Health does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| ELANElanco Animal Health | n/a | n/a | 2.2% | n/a |
| JAZZJazz Pharmaceuticals | 68.1x | n/a | 8.8% | 20.0x |
| BBIOBridgeBio Pharma | n/a | n/a | -3.0% | n/a |
| PCGPG&E | 10.2x | n/a | -8.3% | 17.0x |
| BABoeing | 16.1x | 23.8x | -1.5% | n/a |
| Peer median | 16.1x | n/a | -2.3% | n/a |
- Its free cash flow yield is 2.2%, 4.5 points above the peer median of -2.3%.
The peers are the companies on this site most like ELAN. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- GMABGenmabShares: High debt, Regulation and courts
- Intrinsic value
- Far above intrinsic value (AI estimate)
- Gap
- Slow
- JAZZJazz PharmaceuticalsShares: Regulation and courts, High debt
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- BBIOBridgeBio PharmaShares: Regulation and courts, High debt
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- PCGPG&EShares: Regulation and courts, High debt
- Intrinsic value
- Far below intrinsic value
- Gap
- Will probably not close
- HONAHoneywell AerospaceShares: High debt, Regulation and courts
- Intrinsic value
- Deep below intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star ELAN or pass, then go on to the next one.